Multiple lines of evidence have provided compelling evidence for the existence of a tumor suppressor gene (TSG) on chromosome 7q31.1. ST7 may be the target of this genetic instability but its designation as a TSG is controversial. In this study, we show that, functionally, ST7 behaves as a tumor suppressor in human cancer. ST7 suppressed growth of PC-3 prostate cancer cells inoculated subcutaneously into severe combined immunodeficient mice, and increased the latency of tumor detection from 13 days in control tumors to 23 days. Re-expression of ST7 was also associated with suppression of colony formation under anchorage-independent conditions in MDA-MB-231 breast cancer cells and ST7 mRNA expression was downregulated in 44% of primary breast cancers. Expression profiling of PC-3 cells revealed that ST7 predominantly induces changes in genes involved in re-modeling the extracellular matrix such as SPARC, IGFBP5 and several matrix metalloproteinases. These data indicate that ST7 may mediate tumor suppression through modification of the tumor microenvironment.
Introduction
Numerous independent cytological, molecular genetic and functional studies have provided compelling evidence for the existence of a key tumor suppressor gene (TSG) within a 1-2 megabase region on human chromosome 7q31.1. Deletions involving this region have been observed in virtually every major tumor type, with loss of heterozygosity (LOH) found in up to 80% of breast (Bieche et al., 1992; Zenklusen et al., 1994a) , prostate (Zenklusen et al., 1994c; Latil et al., 1995; Takahashi et al., 1995) , pancreatic (Achille et al., 1996) , colon (Zenklusen et al., 1995a) , ovarian (Zenklusen et al., 1995b) , and thyroid cancers (Zhang et al., 1998) , with lower frequencies in renal cancers (Shridhar et al., 1997) and squamous cell carcinomas of the head and neck (Zenklusen et al., 1995a) . Functional studies using microcell-mediated transfer of chromosome 7 have shown that introduction of a normal copy of chromosome 7 can restore senescence to human fibroblasts (Ogata et al., 1993) and suppress tumorigenicity of a murine squamous cell carcinoma cell line and the human prostate carcinoma cell line, PC-3 (Zenklusen et al., 1994b; Zenklusen et al., 2000) . Furthermore, deletion mapping of PC-3/hchr7 tumors obtained after reversion to the malignant phenotype revealed a common region of loss at 7q31.1, therefore providing compelling evidence for a TSG in this region (Zenklusen et al., 2000) . The gene Suppressor of Tumorigenicity 7 (ST7), also known as RAY1/HELG (Hughes et al., 2001; Vincent et al., 2000) , has emerged as the leading contender for the 7q31.1 TSG (Zenklusen et al., 2001) .
The genomic organization of ST7 comprises 16 exons spanning more than 220 kb, gives rise to four predominant transcripts which we have designated as variants 1a (AF234882), 1b (NM021908), 2a (AY009152) and 2b (AY009153). There are two alternative 5 0 UTR and start codons for exon 1. Exon 1, identified in RAY1 by Vincent et al. (2002) , is present in both ST7-1a and 1b, while the alternative exon 1 is present in both ST7-2a and 2b. An alternatively spliced exon 7 is absent in ST7-1a and 2b. An alternative 3 0 end has been documented in ST7-1b, designated as exon 16b. The most abundant splice variant is ST7-1a, which encodes a 554 aminoacid protein. The other splice variants encode proteins ranging between 511 and 585 amino acids (Vincent et al., 2002) . Whether the different splice variants of ST7 possess different functions is currently unknown. ST7 is ubiquitously expressed in human tissues including the heart, brain, prostate and gastrointestinal tract (Zenklusen et al., 2001; Vincent et al., 2002) . It is highly conserved across species with homologs identified in the mouse, rat, cow, pig, chicken, puffer fish, fruit fly and nematode (Vincent et al., 2000; Zenklusen et al., 2001) . The human and mouse ST7 genes share similar splicing patterns, and the predicted protein products share a remarkable 98% homology (Vincent et al., 2000) . This suggests that ST7 plays a highly conserved role in critical cellular processes, a common feature of most TSGs. In silico analysis of the predicted amino-acid sequence has suggested that the encoded protein assumes a basic globular structure, with a predicted molecular weight of 60.3 kDa and an isoelectric point of 8.10. The secondary structure has been predicted to contain 12 a-helices and four turns (Zenklusen et al., 2001) . Searches to date have failed to identify any known functional domains or motifs or significant homology with any other gene with the exception of the recently cloned ST7 homolog, ST7R, on chromosome 1 (Katoh, 2002) . To date, studies to elucidate the role of human ST7 or its orthologs have not been performed, therefore the function of ST7 remains unknown.
The identity of the true 7q31.1 TSG has remained controversial since we and others (Hughes et al., 2001; Thomas et al., 2001; Brown et al., 2002; Dong and Sidransky 2002) could not substantiate the existence of somatic mutations of ST7 in primary human cancers or cancer cell lines that were initially reported (Zenklusen et al., 2001) . Since somatic mutations in ST7 are rare, we assume that its primary mechanism of inactivation is via epigenetic downregulation, haplo-insufficiency or posttranslational modification of the ST7 protein. In this study, we have investigated the function of the predominantly expressed variant, ST7-1a, in prostate and breast cancer cells and tumors as well as the mechanism through which ST7-1a mediates tumor suppression. We show that ST7-1a mediates suppression of tumorigenicity in both prostate and breast cancer cells, supporting a broad-range tumor suppressor role. Furthermore, re-expression of ST7-1a in PC3 cells profoundly alters the transcriptional profile of genes involved in maintenance of the extracellular matrix.
Results
In vitro and in vivo proliferation characteristics of ST7-1a-transfected PC-3 cells In view of the discrepancy between the original report of the existence of somatic mutations and subsequent studies we first sought to authenticate the in vivo suppression capability attributed to ST7. Northern blotting analysis was performed using the full-length ST7-1a cDNA as a probe, which detects all ST7 splice variants. The hybridization profile shows that ST7 is expressed to varying degrees in all 19 cancer cell lines tested with transcripts ranging in size from approximately 1.5 to 4.0 kb, consistent with the known existence of multiple splice variants (Figure 1 ) (Zenklusen et al., 2001; Vincent et al., 2002) . Previous studies have shown that expression of ST7 mRNA is reduced in cancer cell lines compared to normal primary human tissues (Zenklusen et al., 2001; Vincent et al., 2002) and our data show that relative to other cancer cell lines, expression of ST7 was lowest in PC-3 cells, validating its use as a recipient in re-expression experiments. In the absence of any information regarding functional differences between isoforms of ST7, all experiments were performed using ST7 splice variant 1a (ST7-1a), which is the predominantly expressed transcript (Vincent et al., 2002) . ST71a cDNA was cloned into the pcDNA3.1 mammalian expression vector tagged with the V5 epitope and transfected into PC-3 cells under G418 selection. PC-3 clones harboring an intact integrated construct were identified by PCR amplification of genomic DNA using an ST7-1a-specific primer set. These clones were assessed for expression of ectopic ST7 protein by Western blotting using an anti-V5 antibody. Four PC-3/ST7-1a clones were identified showing varying levels of protein expression (Figure 2a ). In addition, five control PC-3 clones containing the empty pcDNA3.1-vector alone were isolated. Q-PCR demonstrated that on average the ST7 transfectants expressed 19-fold more ST7 mRNA than empty vector controls.
The effect of ST7-1a on the in vivo tumorigenic potential of PC-3 cells was assessed in SCID mice. Five PC-3/pcDNA3.1 control clones and four PC-3/ST7-1a clones were each pooled and injected subcutaneously into the flanks of SCID mice. Tumor growth of PC-3/ ST7-1a cells were dramatically suppressed with a highly significant increase in tumor latency of 2371.7 days compared with the control clones of 1373.0 days MDA-MB-231 PC-3  MDA-MB-435 MDA-MB-453 MCF7   OVCAR-3  ZR75-1  SKOV-3 JAM PEO1 HCT116 LIM1899 LIM1863 LIM2405 LIM2537 HT29 SW620 SW480 SKBR3   ST7   GAPDH B r e a s t O v a r i a n C o l o n B r e a s t P r o s t a t e ST7 expression relative to PC-3 Figure 2b ). PC-3/ST7-1a cells also exhibited a significant delay in the time required for the tumor volume to reach 500 and 900 mm 3 (Students' t-test, Po0.0001; Figure 2c ). Tumors that arose in mice injected with PC-3/ST7-1a cells were all shown by Western blots to retain expression of exogenous ST7 protein (data not shown).
The effect of ST7-1a expression on in vitro growth was assessed. Re-expression of ST7-1a had no significant effect on the anchorage-dependent proliferation rate of PC-3 cells. PC-3/ST7-1a cells had a mean doubling time of 39.173.7 h compared to the control clones of 48.0717.4 h. Anchorage-independent colony formation was reduced by 40% in PC-3/ST7-1a clones but this did not reach statistical significance (Student's t-test, P ¼ 0.09) (Figure 3a) .
In vitro proliferation characteristics of ST7-1a-transfected breast cancer cells MDA-MB-231 It has been suggested that ST7 may represent a multitissue tumor suppressor since genomic alterations have been observed at the 7q31 locus in a variety of tumor types. Therefore, we sought to investigate the role of ST7-1a as a tumor suppressor in breast cancer since this is one of the tumor types where LOH at 7q31 has been reported to occur frequently (Bieche et al., 1992) . MDA-MB-231 cells, which express low levels of ST7 mRNA (Figure 1 ), were transfected with ST7-1a and five MDA-MB-231/ST7-1a expressing clones and five MDA-MB-231/pcDNA3.1 control clones were obtained. Again the ST7-1a-transfected cells showed no significant difference in anchorage-dependent proliferation rate with a mean doubling time of 4174.0 h for a pool of five independent MDA-MB-231/ST7-1a clones compared to 3976.4 h for a pool of five independent pCDNA3.1 control clones (mean7s.e.m., n ¼ 3). However, anchorage-independent proliferation of MDA-MB-231/ST7-1a cells was suppressed with a 2.470.22-fold reduction in colony number (Students' t-test, Po0.05, n ¼ 3) (Figure 3a matching control tissues, and using an arbitrary 1.5-fold cutoff, 44% of the cancer tissues showed decreased expression (1.9-to 60-fold) (5/15 ductal and 3/3 lobular carcinomas) while four ductal carcinomas showed upregulation (1.5-to 3.1-fold).
Exogenous expression of ST7-1a in PC-3 induces changes in gene expression We sought to identify the target genes and pathways involved in ST7-mediated tumor suppression of PC-3 cells. This was achieved by array-based expression analysis using Affymetrix U133 plus 2.0 arrays in four independent PC-3/ST7-1a clones and the pool of five PC-3/pcDNA3.1 controls. Total RNA from the five PC-3/pcDNA3.1 clones was pooled to generate a control array. Expression data were analysed using GeneChip Operating Software (GCOS, Affymetrix) and GeneSpring 7.2 (Silicon Genetics). The frequency of increased or decreased gene expression changes was determined by comparing of each PC-3/ST7-1a clone with the pooled PC-3/pcDNA3.1 control. Three-hundred and twentythree genes (100 upregulated and 223 downregulated) were identified, which showed a greater than twofold expression change in at least three of four PC-3/ST7-1a clones (Supplementary Table 1) . Clustering these 323 genes according to gene ontology using the online version of EASE software (EASEonline), revealed 10 functional categories with EASE scores of o0.05 (Table 1) . Details of the genes classified into these 10 categories are shown in Table 2 . Strikingly, the top three categories were all related to the extracellular matrix. Key genes involved in this process that showed differential expression are interstitial extracellular matrix components FN1 (2.7-fold downregulated), COL1A1 (4.2-fold downregulated), SPARC (5.9-fold downregulated), ChGn (2.6-fold downregulated), ANK3 (3.5-fold downregulated), as well as remodeling enzymes MMP-1, -10, -13 (6.7-, 4.3-and 4.8-fold downregulated, respectively). Interestingly, expression of the basement membrane-related proteins LAMB3 and COL4A3BP were upregulated (both 2.56-fold). Cell differentiation status was also altered, reflected in upregulation of the EMT-inducing factor SNAI2 (2.75-fold upregulated) and the mesenchymally expressed CDH11 (2.5-fold upregulated).
Verification of gene expression changes identified by Affymetrix expression analysis
Gene expression changes identified by Affymetrix gene expression analysis were validated both at the mRNA transcript and protein level. Two upregulated genes (SERPINE1 and PODXL) and two downregulated genes (SPARC and IGFBP5) were analysed by realtime Q-PCR. Gene expression was normalized using the ACTA2 gene, which was shown to have unaltered expression across all microarray experiments. As shown in Figure 4a , the Q-PCR results were in concordance with the microarray data. Western blotting was also utilized to assess the protein expression of podocalyxinlike protein (PODXL), secreted protein acidic and rich in cystein (SPARC), Cadherin 11 (CDH11) and MMP13 ( Figure 4b ) and these too were in concordance with the microarray results.
Discussion
There is compelling functional (Ogata et al. , 1993) and genetic evidence for the existence of a broad range tumor suppressor on human chromosome 7q31.1 (Bieche et al., 1992; Zenklusen et al., 1994a Zenklusen et al., , c, 1995a Latil et al., 1995; Koike et al., 1997) . Zenklusen et al. (2001) identified ST7 at the center of the candidate region and provided several lines of evidence suggesting that it was the long sought after 7q31.1 TSG. First, it is ubiquitously expressed in human tissues and is highly conserved across species (from 99.5% in chimpanzee to 72.3% in Drosophila) suggesting that it is involved in a critical cellular process. Second, re-introduction of ST7 into PC-3 cells resulted in suppression of tumorigenicity in a mouse xenograft assay. Finally, truncating somatic mutations were identified in several breast cancer cell lines and in 6/10 primary colorectal cancers. However, these data were PH: Population Hits, the number of genes on the whole chip that are in the specific category.
d PT: Population Total, the number of genes on the whole chip that are in any gene category.
e The upper bound of the distribution of Jackknife Fisher exact probabilities given the List Hits, List Total, Population Hits and Population Total. partially undermined when we (Thomas et al., 2001 ) and others (Hughes et al., 2001; Brown et al., 2002; Dong and Sidransky, 2002; Lu et al., 2003) could not substantiate the existence of somatic mutations of ST7 in any primary human cancers or cancer cell lines. Nevertheless, the absence of somatic mutations does not preclude ST7 as the 7q31 tumor suppressor since abrogation of function may be mediated through epigenetic downregulation, haplo-insufficiency or posttranslational modification. Interestingly, recent evidence suggests that histone methylation may be an important epigenetic modifier of ST7 transcription. The protein arginine methyltransferase 5 (PRMT5) can associate with the BRG1 chromatin remodeler to directly repress transcriptional activation of ST7 through regulating chromatin accessibility (Pal et al., 2004) . Furthermore, exogenous expression of PRMT5 in NIH 3T3 cells induced cell transformation that was associated with a decrease in ST7 expression.
Functional characterization of ST7 CS-F Hooi et al
In this study, we have provided powerful evidence that ST7 functions as a tumor suppressor in both prostate and breast cancer cells. A role for ST7 in breast carcinogenesis is further supported by the finding that it is downregulated in a large proportion of primary breast cancers. These data, together with the observation that LOH at 7q31 is common in many tumor types, supports the proposal that ST7 may behave as a multi-tissue tumor suppressor. Previously we have shown that ST7 mutations are absent from primary breast cancers (Thomas et al., 2001) pointing to the downregulation of ST7 via epigenetic mechanisms. In pilot experiments, we have not detected significant hypermethylation of the ST7 gene promoter in primary breast cancers (unpublished observations) and it is likely that histone acetylation is the predominant mode of regulation of ST7 (Pal et al., 2004) .
Having clearly shown that ST7-1a functions as a tumor suppressor, we sought to elucidate the target genes and pathways involved in ST7-1a-mediated suppression using gene expression profiling. Such strategies are necessary since in silico analyses have not yielded clues as to its normal function (Vincent et al., 2000 (Vincent et al., , 2002 Zenklusen et al., 2001) . Induction of ST7-1a expression in PC-3 cells resulted in a twofold or greater expression change in 323 genes that are structural components of the extracellular matrix, involved in its remodeling, or in cellular differentiation. For example, the SPARC gene, which was downregulated by an average of sixfold in PC-3/ST7-1a transfectants, is a multifunctional calcium-binding glycoprotein also known as osteonectin and BM-40. Roles ascribed to SPARC include regulation of cell adhesion, proliferation, migration, tissue remodeling during wound healing, tumor progression and development (Barker et al., 2005a, b) . SPARC is known to interact with other matrix molecules such as collagen I, vitronectin and thrombospondin and with integrin-linked kinase (Rosenblatt et al., 1997; Barker et al., 2005a) and SPARCdeficient cells were recently found to exhibit defective DNA nuclear excision repair (Kato et al., 2005) . Elevated SPARC expression has been found in many human malignancies including prostate, breast, colon, hepatocellular, head and neck, and non-small-cell lung carcinomas (Le Bail et al., 1999; Thomas et al., 2000; Lussier et al., 2001; Koukourakis et al., 2003; Jones et al., 2004; Chin et al., 2005) . In prostate carcinoma, SPARC expression in cancer cells is associated with bone metastasis (Thomas et al., 2000) . In other cancer types, upregulated expression is restricted to the stroma surrounding the cancer and is strongly associated with poor survival (Koukourakis et al., 2003; Jones et al., 2004) . However, the affect of SPARC on tumorigenesis appears to be cell type dependent as downregulation of SPARC is correlated with malignant progression in some cancers such as neuroblastoma and ovarian cancers (Yiu et al., 2001; Chlenski et al., 2004) . Gene expression is expressed in Log 10 scale as the fold change in 4 PC-3/ST7-1a clones relative to the pool of 5 PC-3/pcDNA3.1 clones, normalized to the endogenous control ACTA2. (b) Western analysis of proteins up or downregulated by microarray in PC-3 clones was carried out on whole cell lysates or cultured conditional media prepared from control PC-3/pcDNA3.1 clones or PC-3/ST7-1a clones. An equivalent amount of protein was resolved by 10% SDS-PAGE, transferred to a nitrocellulose membrane and proteins immunoreactive to antibodies directed against PODXL, CDH11, SPARC or MMP13 were detected by enhanced chemiluminescence.
same model Puolakkainen et al., 2004) . While the precise role of SPARC in tumorigenesis is unclear, the latter data highlights the importance of SPARC in tumor-stromal cell interactions and its influence on tumor progression by regulation of the tumor microenvironment. Consistent with this, we found downregulation of fibronectin 1, collagen type I, ankyrin 3 and several matrix metalloproteinases, (MMP1, MMP10 and MMP13) and upregulation of laminin B3 and collagen type IV alpha 3-binding protein. These composite changes in extracellular matrix signal a dramatic change in the cell histotype, and are very likely to be involved in the reduced tumor growth. Extracellular matrix, through integrin signaling, potently regulates cell proliferation and survival.
Another gene involved in cell adhesion and the cytoskeleton is PODXL, which was upregulated in all four PC-3/ST7-1a clones. PODXL is a transmembrane sialoprotein expressed in foot processes of podocytes and on the luminal surface of vascular endothelium, and has been reported to function as an adhesion molecule involved in lymphocyte recruitment (Sassetti et al., 1998) . It was identified as an endogenous downstream target of the WT1 TSG, mediating glomerular differentiation (Palmer et al., 2001) . PODXL is a target of p53-mediated transcriptional repression in a Wilm's tumor cell line (Stanhope-Baker et al., 2004) .
Importantly, genes involved in growth regulatory pathways were also altered, for example, insulin-like growth factor-binding protein 5 (IGFBP-5, fourfold downregulation) and inhibitor of DNA binding 2 (threefold downregulation). Overexpression of the IGF pathway may play a role in several malignancies (Moschos and Mantzoros, 2002) . There is strong evidence for the involvement of IGFBP-5 in the progression of intestinal epithelial cells to cancer in the APC Min/À mouse model. Overexpression of IGFBP-5 was correlated with progression from normal epithelium to intestinal carcinoma (Paoni et al., 2003) . Many other genes show expression changes consistent with decreased tumorigenicity, such as VEGF receptor 2 (KDR) (Shih et al., 2002) . Overall, the data strongly support a role of ST7 in regulating members of oncogenic pathways. However, it is obvious from the microarray studies that ST7 profoundly modifies the transcriptional milieu of PC-3 cells and more sophisticated time course experiments will be required to elucidate the pathways that are directly influenced by ST7.
In conclusion, we have demonstrated that ST7 functions as a tumor suppressor in prostate and breast cancer cells. However, the rarity of somatic mutations in ST7 among primary cancers or cancer cell lines suggests that epigenetic alterations of ST7 mediated by histone acetylation (Pal et al., 2004) may be the primary mechanism of inactivation. Microarray studies imply that ST7 induces remodeling of the extracellular matrix indicating that ST7 mediates tumor suppression by changing the tumor microenvironment, which is now recognized as an important factor in determining the malignant potential of cancer cells. Many of the genes altered are known tumor suppressors or modifiers of tumor behavior but the specific mechanism through which ST7 mediates tumor suppression remains unclear. Further dissection of the function of ST7 may uncover a novel tumor suppression pathway.
Materials and methods

Cell lines
The cancer cell lines analysed included six breast (SKBR-3, ZR75-1, MDA-MB-453, MDA-MB-435, MDA-MB-231, MCF7), eight colon (HCT116, LIM1899, LIM1863, LIM2405, LIM2537, HT29, SW620, SW480), four ovarian (SKOV-3, JAM, OVCAR-3, PEO1) and one prostate (PC-3). Cell lines were maintained in RPMI 1640 with HEPES media supplemented with 10% (v/v) fetal bovine serum. Stable transfectants were maintained in medium containing 400 mg/ ml G418 (Invitrogen, Paisley, England). Transfection experiments with MDA-MB-231 cells were performed on a subclone with a phenotype representative of parental cells.
Transfection of ST7-1a-containing expression vectors
The ST7 splice variant 1a (ST7-1a) cDNA corresponding to the reference sequence AF234882 was generated by PCR from cDNA derived from the SW480 colon cancer cell line using the primers 5 0 -AGCAAGTTCAGCCTGGTTAAGT-3 0 and 5 0 AATACTCATAAAGAAGGTCCC-3 0 and then cloned into the pcDNA3.1. V5-His B vector. This generated an ST7-1a construct with a V5 tag at the C-terminus to allow the ectopic protein to be detected using a V5 antibody in the absence of an available ST7-specific antibody. The integrity of the cDNA clone was verified by sequencing in both directions. PC-3 cells were seeded into 24-well dishes (2 Â 10 5 cells per well) and transfected the following day with 1 mg of ST7-1a-pcDNA3.1/ V5-His expression vector or the empty-vector alone using 2 ml Lipofectamine (Invitrogen). After 24 h, the culture medium was supplemented with 400 mg/ml G418 (Gibco BRL, Grand Island, NY, USA) for a period of 3 weeks when discrete colonies were isolated by trypsinization. All clones were maintained in selective medium. Each clone was assayed for the presence of an intact integrated cDNA construct by multiplex PCR using primers specific for the ST7-1a cDNA (ST71a285F; 5 0 -GACCGTGTGGTTCTTCATCGT-3 0 ; ST71a 1398R 5 0 TTTGGCACATGAGGATTTGA-3 0 ) as well as for microsatellite marker D22S1154 (D22S1154F; 5 0 -GCCTAA CCTGTGATTGTTTCATCTA-3 0 ; D22S1154R 5 0 -TGGCG AATTGATTCTCACCTA-3 0 ) which acted as an internal control. Of DNA, 50 ng was used in a 10 ml volume containing 1 Â PCR reaction buffer, 10 mM dNTPs, 1 mM forward and reverse primers (ST71a285F and ST71a1398R, respectively), 0.6 mM chromosome 22 forward and reverse primers (D22S1154F and D22S1154R, respectively), and 1U Taq (Hotstar, Qiagen Inc., Valencia, CA, USA). The following profile was used during amplification: 10 min at 941C, 35 cycles of 941C for 25 s, 581C for 30 s, and 721C for 2 min and then 721C for 5 min.
DNA and RNA isolation Genomic DNA was isolated from cultured cells using the DNeasy Tissue Kit (Qiagen, Hilden, Germany). Total DNA was quantified by measuring the absorbance at 260 nm. For RNA extraction, cells were grown in a 175 cm 2 flask and harvested once they reached a confluency of 70-80%. RNA was isolated using phenol-chloroform (Trizol, Invitrogen Corporation, Carlsbad, CA, USA) followed by column chromatography (RNeasy, Qiagen Inc., Valencia, CA, USA). The RNA was ethanol precipitated and quantified using a Nanodrop spectrophotometer (Biolab, Mulgrave, VIC, Australia).
Northern blot analysis
Of RNA, 20 mg from a series of human tumor cell lines were electrophoresed on a 1% agarose/formaldehyde gel and transferred to a GeneScreen Plus s membrane (NENt Life science Products, Boston, USA) and baked at 801C for 2 h. The blots were hybridized with a full-length ST7-1a probe (Accession no AF234882), and radiolabeled using the DECAprime II random primed DNA labeling kit (Ambion, Austin, TX, USA). The probe was purified through a MicroSpin G-50 column (GE Healthcare, Piscataway, NJ, USA) to remove unincorporated nucleotides. Pre-hybridization, hybridization and washing were performed according to the manufacturer's recommendation. The blots were autoradiographed and analysed with the FX Molecular Imager (Bio-Rad). RNA loading in each lane was assessed by probing with GAPDH cDNA.
Western blotting
Of whole cell lysates, 50-75 mg were subjected to 10% SDS-PAGE and the separated proteins transferred to ECL nitrocellulose membrane (GE Healthcare, Piscataway, NJ, USA). Membranes were blocked with 5% (w/v) non-fat milk The blots were washed with TBS-T, followed by detection with either HRP-conjugated anti-mouse or anti-rabbit immunoglobulins (1:2000 dilution). Bound antibody was detected using an enhanced chemiluminescence Western analysis kit (Amersham Pharmacia Biotech, Buckinghamshire, England). For Western blotting of secreted protein MMP-13, SPARC and CDH11, 3 Â 10 5 cells were seeded in 60 mm Petri dish and on reaching 80% confluency were cultured for a further 48 h in fetal bovine serum-free media. Cells and supernatants were then harvested and analysed on Western blots as described above. The appropriate volume of conditional media normalized to same cell number was loaded on the gel.
Anchorage-dependent growth
The proliferation rate of cell lines was determined using the CellTiter 96 Aqueous Non-radioactive Cell Proliferation Assay according to the manufacturers' instructions (Promega, Madison, WI, USA) by plating 5000 cells into each well of a 96-well plate in triplicate. Cell growth determinations were made every 24 h over 4 days by the addition of 20 ml of the combined MTS/PMS solution and the optical density measured at 490 nm. The doubling time for each clone was calculated during the period of linear growth using the equation: 0.69(T)/Ln N f ÀLn N i , where T is the time between observations and N is the relative cell number at the final reading (f) and the initial reading (i) (Kruzelock et al., 2000) .
Anchorage-independent growth Anchorage-independent growth was assessed by plating 2000 or 3000 cells in 0.5 ml of 'top' agar over 0.5 ml of 'bottom' agar in 24-well culture dishes in triplicate. The 'top' agar consisted of 0.3% (w/v) Bacto agar (Becton Dickinson, Sparks, MD, USA) in RPMI 1640 supplemented with 20% (v/v) fetal bovine serum, 2 mM L-glutamine and 400 mg/ml G418. The 0.5% (w/v) 'bottom' agar contained standard culture medium supplemented with 400 mg/ml G418. The 'top' agar was overlaid with 1 ml of standard culture media containing 400 mg/ml G418 and colonies allowed to grow at 371C in 5% CO 2 for up to 30 days. Colonies greater than 30-50 cells were scored in 10 independent fields per well. At least two independent experiments were performed for each clone. Images were captured using DIC microscopy at Â 100 magnification with an Olympus inverted system microscope IX81 IX2 series.
In vivo tumorigenicity assays Male severe combined immunodeficiency (SCID) mice (4-6 weeks old) were used to perform in vivo tumorigenicity assays. Fifteen mice were injected with a pool of five independent empty pcDNA3.1-V5-His vector clones or a pool of four independent ST7-1a-transfected clones. Each animal received 2 Â 10 6 pooled cells in 50% (v/v) matrigel (BD Biosciences, Bedford, MA, USA) in PBS subcutaneously on the left flank. The tumor length and width was measured three times a week. The tumor volume was calculated as p/6 Â length Â width 2 .
Affymetrix expression arrays
The Affymetrix Human Genome U133 Plus 2.0 set of arrays (Affymetrix, CA, USA) was used for the expression analysis. This series has the coverage of 54 675 probe sets, each of which is designed to assay a RNA transcript. The biotinylated cRNA preparation, hybridization, and scanning of microarrays were performed by Australian Genome Research Facility Ltd (AGRF). The scanner operating software, GCOS, converts the signal on the chip into a DAT file, which will then be used for generating subsequent CEL and CHP files for analysis. The CEL file was imported in GeneSpring and data were normalized using GC-RMA algorithm. EASEonline was used to assign the identified genes to categories based on Gene Ontology and to test statistically for significant co-regulation in each biological process category. The identified genes were further analysed using DAVID (database for annotation, visualization and integrated discovery) (Dennis et al., 2003) .
Real-time Q-PCR mRNA expression levels in PC-3 pcDNA3.1, ST7-1a clones or 18 paired primary breast tumors and matching normal tissue was determined using real-time PCR. mRNA analysis was performed on reverse-transcribed RNA using M-MLV transcriptase RNase H Minus with primers dVT recognizing poly-A tails of RNA sequences. Of cDNA template, 4 mg was used in a 20 ml reaction volume containing 10 ml SYBR Green reagent (Applied Biosystems, Foster City, CA, USA) and 1 mM each of the forward and reverse primers specific for each gene. The forward and reverse primer sequences for genes analysed are as follows: ACTA (NM_001613), 5 0 -ATCAAGAT CATTGCCCCTCCG-3 0 , 5 0 -GCTGATCCACATCTGCTGG AAG-3 0 ; SERPINE1 (NM_000602.1), 5 0 -TCTGCAGACCTG GTTCCCAC-3 0 , 5 0 -GCCCCGTAGTTCCATCCTG-3 0 ; POD XL (NM_005397), 5 0 -gcatggaggacacagatgactc-3 0 , 5 0 -ttcagaccc ctgtccactaaga-3 0 ; SPARC (NM_003118.2), 5 0 -CTTTTGGGA GCACGGACTGT-3 0 , 5 0 -CAGGATGCGCTGACCACTT-3 0 , IGFBP5 (NM_000599.2), 5 0 -GACCGCAAAGGATTCTA CAAGAG-3 0 , 5 0 -CTTGTCCACGCACCAGCA-3 0 . Quantitative PCR was performed on an ABI PRISM 7000 Sequence Detection System apparatus (Applied Biosystems, Foster City, CA, USA) and cDNA quantified using a standard curve constructed with cell line cDNA and normalized to ACTA2 gene expression. For the analysis of ST7-1a expression in breast tumors, gene expression was normalized to the B2M (5 0 -CTCGCTCCGTGGCCTTAG-3 0 , 5 0 -TGAAACCCAGA CACATAGCAATTC-3 0 ) gene.
Patients and samples
Tumor and normal specimens were collected from patients undergoing surgery for primary breast cancer at Western Hospital (Victoria, Australia). Tumors were resected together with the corresponding normal tissue collected 45 cm from the macroscopic tumor margin. Tissues were fresh frozen in liquid nitrogen and stored at À801C until use. The tumors were comprised of 15 ductal and three lobular carcinomas.
